Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine For The First Line Treatment of Metastatic or Locally Advanced Unresectable Adenocarcinoma of The Pancreas: A Phase II Randomized Study

NCT03807999 is registered in ClinicalTrials.gov with Hacettepe University as lead sponsor.

NCT NCT03807999
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03807999 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine For The First Line Treatment of Metastatic or Locally Advanced Unresectable Adenocarcinoma of The Pancreas: A Phase II Randomized Study
Lead sponsor
Hacettepe University
Phase
Phase 2
Overall status
Completed
Start date
February 19, 2015
Completion date
November 1, 2018
Enrollment
125 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic neoplasm